Maintenance with PARP inhibitor is the way forward in ovarian cancer:Median PFS in platinum sensitive relapse carcinoma ovary is approximately 10 months.20% of high grade serous carcinoma ovary have somatic or germline mutation in BRCA gene.Sin

Genetic testing for breast and ovarian Cancer1)what is genetic testing?Answer:-Genetic make up of an individual is like a house map.Any abnormality in the house map will lead to a faulty construction of the house, similarly any abnormality in the

A case report of newly diagnosed epithelial ovarian carcinoma presenting with spontaneous tumor lysis syndrome and its successful management with rasburicaseDr Deepak Kumar Shuklahttp://www.ijmpo.org/text.asp?2017/38/3/360/216841

Bevacizumab is the first antiangiogenic therapy to be approved in advanced adenocarcinoma lung in combination with chemotherapy. Dose used in different trial was different and varied from 7.5 mg/kg 3 weekly to 15 mg/kg every 3 weeks. Chemotherapy par

Now long term survival is possible in some stage IV solid cancers with the use of targeted, hormonal, chemotherapy drugs. The list includes:1) Stage IV hormone receptor positive metastatic breast cancer.2) Stage IV her2 nu positive metastatic breas

Decoding Lynch syndrome -- Colorectal cancer(CRC)Lynch syndrome is the most common cause of inherited Colorectal cancer (CRC-large intestine cancer). It constitutes 3% of all newly diagnosed colorectal cancer burden.In lynch syndrome there is ger

In india 14-20 percent lung cancer patients are wrongly diagnosed and treated as pulmonary tuberculosis leading to delay in treatment. Burden of ALK positivivity in unselected adenocarcinoma lung is low.(4 percent)But in selected group of never o

Median survival in metastatic carcinoma breast is 2 years.5 year survival is close to 25% (i.e. one out of 4 patients of metastatic breast cancer will be alive at 5 years).New Class of drugs - CDK4 & 6 inhibitor (Palbociclib, Ribociclib) have bee